Categories Analysis, Health Care

Earnings preview: What’s on the cards for Biocept in Q4

Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours. Analysts expect the commercial-stage molecular oncology diagnostics company to report a wider loss of $1.50 per share, compared to 18 cents per share it reported in the year-over quarter.

Revenue is projected to decline by 4.5% year-over-year to $0.95 million.

Image for representation (Courtesy: Louis Reed/Unsplash)

During the last reported quarter, the top line tumbled 31.5% to $762 million. Though net loss narrowed during this quarter to  $2.42 per share from $5.90 per share, it was still wider than the street expectation of a loss of $2.02 per share.

BIOC shares have fallen 90% in the trailing 52 weeks. A 10% increase in stock price since the beginning of this year has given a breather to Biocept investors.

This year’s stock price rise was spurred by a 13% rally on March 26, when the San Diego, California-based firm announced that it was expanding its Empower TC into urology. The platform would now be used to diagnose prostate cancer by performing biomarker tests.

READ: AFFIMED CUTS DOWN LOSSES IN 2018

CEO Michael Nall said following this announcement, “We believe that our pathology partnership platform offers urologists and uropathologists a unique solution to evaluate and treat their patients diagnosed with prostate cancer, which further distinguishes Biocept from other commercial liquid biopsy services.”

Maxim Group analyst Jason McCarthy recently launched his coverage of the stock with a Buy rating and a price target of $3. The average price target on the stock suggests a 400% upside from the last close, signifying analyst confidence in it.

 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top